Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Business

Laverock Therapeutics raises £13.5M to develop unique gene silencing platform for programmable advanced therapies

by September 28, 2023
September 28, 2023
Laverock Therapeutics raises £13.5M to develop unique gene silencing platform for programmable advanced therapies

Laverock Therapeutics, established to commercialise the gene editing induced gene silencing platform for all human therapeutic applications has announced it has expanded its seed funding round to £13.5M.

This investment was led by Calculus Capital with additional participation by Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund and Tekfen Ventures.

The funding will enable further development of the GEiGS technology and progression of Laverock’s programmes in regenerative medicine and immuno-oncology, with a focus on Type I Diabetes and solid tumour responsive T-cell and macrophage based immune therapies, through to in vitro and in vivo validation. A key part of this next phase will be bringing on new members of the team and expanding lab facilities.

David Venables, CEO of Laverock, commented: “GEiGS is already showing significant potential to transform the safety and efficacy of advanced therapies and we are excited that this new investment will allow us to progress towards pre-clinical candidate selection. We’re pleased to welcome such an experienced group of investors on board, bringing extensive sector expertise which will help us to grow as a company and accelerate the development of targeted, responsive treatments.”

Elizabeth Klein, Investment Director at Calculus, said: “We are delighted to support Laverock and its exceptional management team, led by CEO David Venables, as the company embarks on its next phase of expansion, pioneering a new era of programmable advanced therapies. We backed David’s previous venture, Synpromics, which delivered an exceptional return for Calculus investors in 2019. Laverock’s ambitious plans hold tremendous potential for the healthcare sector, and we are excited to be part of the journey.”

Read more:
Laverock Therapeutics raises £13.5M to develop unique gene silencing platform for programmable advanced therapies

0
FacebookTwitterGoogle +Pinterest
previous post
Ditching the crystal ball on a potential government shutdown
next post
One in five SME owners planning to sell part or all of business by 2025

You may also like

Stéphane Bellucci: Insights from a Leader in Specialty...

August 23, 2024

Windfall tax revenue set to slump 40 per...

June 27, 2023

Mid-year slump in business confidence confirmed by July...

July 31, 2023

Shops and restaurants brace for record employment tax...

January 3, 2025

Tesco accelerates price cuts amid easing inflation and...

October 4, 2024

Fixed-Fee vs Hourly Rate: How Conveyancing Solicitor Fees...

February 5, 2025

Bitcoin surges past $80,000 as Trump nears control...

November 11, 2024

Affiliate Marketing Spreading Across A Spectrum Of Industries...

May 21, 2025

Make UK investment screening ‘more business friendly’ says...

November 13, 2023

Two million self-employed workers face pension crisis, warns...

September 9, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • ‘Bold’ general who led US’ ‘Midnight Hammer’ strikes on Iran ends Middle East reign

      August 25, 2025
    • Democrats opposed John Bolton for years — until they sought him as an ally against Trump

      August 25, 2025
    • Top GOP senator defies Trump demand to bend Senate rules for his court picks

      August 25, 2025
    • Patients Using Popular Meds May Face a Tariff Hit: US–EU Trade Deal Targets Branded Drugs Like Ozempic and Wegovy

      August 25, 2025
    • What Automatic Planning and Scheduling Means for Your Projects

      August 25, 2025
    • Ultimate Traders Review: Easy and Effective Prop Trading

      August 25, 2025

    Categories

    • Business (8,876)
    • Investing (2,236)
    • Politics (16,481)
    • Stocks (3,228)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved